Janssen-Cilag discontinues Comfyde for epilepsy
02 February 2010
Katie McQue
Please Login to read the full article.
02 February 2010
Katie McQue
katie.mcque@informa.com
Janssen-Cilag ( Johnson & Johnson) has withdrawn an EU marketing application for its troubled anticonvulsant Comfyde (carisbamate) for the treatment of partial onset seizures in patients with epilepsy and discontinued developing it for the treatment of epilepsy.
The drug is remains in Phase...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA panel backs expanded use of GSK seizure drug, supports historical controls
- Upsher-Smith begins Phase III trial of intranasal midazolam for epilepsy seizure clusters
- US expanded label for UCB anti-epileptic 'a reflection of patient centric culture'
- Disheartened investors put UTHR shares to the rack on FREEDOM-C2 failure
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
